SCIDAR - A Digital Archive of the University of Kragujevac
A digital archive of the University of Kragujevac contains easily searchable and up-to-date research results.
Please use this identifier to cite or link to this item:
https://scidar.kg.ac.rs/handle/123456789/9355Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.rights.license | openAccess | - |
| dc.contributor.author | Jakovljevic, Mihajlo | - |
| dc.date.accessioned | 2020-09-19T18:05:57Z | - |
| dc.date.available | 2020-09-19T18:05:57Z | - |
| dc.date.issued | 2014 | - |
| dc.identifier.issn | 0350-1221 | - |
| dc.identifier.uri | https://scidar.kg.ac.rs/handle/123456789/9355 | - |
| dc.description.abstract | © 2014, Serbian Medical Society . All rights reserved. Possible net savings achieved via generic substitution of brand name drugs within the EU healthcare expenditure amount to € 30 billion. In the course of the past 5 years, some of the leading therapy classes, such as oncologics, antihypertensive, antidiabetics, lipid regulators, antipsychotics, platelet aggregation inhibitors, antiulcerants and a few others, experienced fierce generic competition, when blockbuster patents expired. This review aims to describe contemporary circumstances within the leading global generic markets. | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
| dc.source | Medicinski Casopis | - |
| dc.title | Recent developments in the world’s leading generic markets | - |
| dc.type | article | - |
| dc.identifier.doi | 10.5937/mckg48-5071 | - |
| dc.identifier.scopus | 2-s2.0-84943607983 | - |
| Appears in Collections: | Faculty of Medical Sciences, Kragujevac | |
 | Page views(s)505 | Downloads(s)35 |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.5937-mckg48-5071.pdf | 137.66 kB | Adobe PDF |  View/Open |
This item is licensed under a Creative Commons License
